Literature DB >> 2010101

Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer.

E Burghardt1, F Girardi, M Lahousen, K Tamussino, H Stettner.   

Abstract

One hundred eighty patients with ovarian cancer underwent complete pelvic lymphadenectomy (n = 75) or pelvic and paraaortic lymphadenectomy (n = 105). Twenty-one patients underwent a preoperative biopsy of the scalene lymph nodes. The incidence of positive lymph nodes was 24% in stage I (n = 37), 50% in stage II (n = 14), 74% in stage III (n = 114), and 73% in stage IV (n = 15). Of the 105 patients who underwent pelvic and paraaortic lymphadenectomy, 13 (12%) had positive pelvic and negative paraaortic nodes and 10 (9%) had positive paraaortic and negative pelvic nodes. Positive scalene nodes were found in four patients (19%) later shown to have stage IV disease. One hundred forty patients were studied for number of involved nodes and node groups, size of nodal metastases, residual tumor, and survival. Of the 81 patients with positive nodes, most had only one or two positive node groups or one to three positive individual nodes. A few patients had seven to eight involved node groups with up to 44 positive nodes. Greater numbers of positive nodes were found in stage III than stage IV. The size of the largest nodal metastasis was not related to the clinical stage or survival, but did correlate with the number of positive nodes. Stage III patients with no residual tumor had a significantly lower rate of lymph node involvement than those with tumor residual (P less than 0.01). Actuarial 5-year survival rates of patients with stage III disease and no, one, or more than one positive nodes were 69, 58, and 28%, respectively.

Entities:  

Mesh:

Year:  1991        PMID: 2010101     DOI: 10.1016/0090-8258(91)90099-q

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  33 in total

Review 1.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  Kenneth Jaaback; Nick Johnson; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

Review 2.  Management of retroperitoneal lymph nodes in the treatment of ovarian cancer.

Authors:  Kimio Ushijima
Journal:  Int J Clin Oncol       Date:  2007-06-27       Impact factor: 3.402

Review 3.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Authors:  Kazuaki Takahashi; Masataka Takenaka; Ayako Kawabata; Nozomu Yanaihara; Aikou Okamoto
Journal:  Int J Clin Oncol       Date:  2020-01-27       Impact factor: 3.402

4.  Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Authors:  Takafumi Oshita; Hiroaki Itamochi; Ryuichiro Nishimura; Fumitaka Numa; Kazuhiro Takehara; Masamichi Hiura; Hirotoshi Tanimoto; Jun Noma; Ryoji Hayase; Akihiro Murakami; Hideo Fujimoto; Yasunobu Kanamori; Fuminori Kitada; Keiji Shitsukawa; Makoto Nagaji; Yukihisa Minagawa; Michihisa Fujiwara; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2012-10-17       Impact factor: 3.402

5.  Prognosis and conditional disease-free survival among patients with ovarian cancer.

Authors:  Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

6.  Perimenopausal ovarian carcinoma patient with subclavian node metastasis proven by immunohistochemistry.

Authors:  Hee Jeong Jeong; Hyun Joo Kim; Eun Hee Lee; Hyoun Wook Lee; Min Kyu Kim
Journal:  J Menopausal Med       Date:  2014-04-28

7.  Elevated expression of MAC30 predicts lymph node metastasis and unfavorable prognosis in patients with epithelial ovarian cancer.

Authors:  Shanshan Yang; Huiyan Li; Yunduo Liu; Xiaoming Ning; Fanling Meng; Min Xiao; Deying Wang; Ge Lou; Yunyan Zhang
Journal:  Med Oncol       Date:  2012-12-18       Impact factor: 3.064

8.  Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.

Authors:  Amy D Tiersten; P Y Liu; Harriet O Smith; Sharon P Wilczynski; William R Robinson; Maurie Markman; David S Alberts
Journal:  Gynecol Oncol       Date:  2009-01-12       Impact factor: 5.482

9.  Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer.

Authors:  Su-Jin Baek; Jeong-Yeol Park; Dae-Yeon Kim; Jong-Hyeok Kim; Yong-Man Kim; Young-Tak Kim; Joo-Hyun Nam
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

10.  Fertility preservation in patients with early epithelial ovarian cancer.

Authors:  Yong-Soon Kwon; Ho-Suap Hahn; Tae-Jin Kim; In-Ho Lee; Kyung-Taek Lim; Ki-Heon Lee; Jae-Uk Shim; Jung-Eun Mok
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.